Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months SoonerGlobeNewsWire · 1 day ago
Why Humacyte, Inc. (HUMA) Outpaced the Stock Market TodayZacks Investment Research · 3 days ago
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research · 4 days ago
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by HospitalsGlobeNewsWire · Oct 15, 2026
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research · Oct 13, 2026
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You TradeZacks Investment Research · Oct 6, 2026Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.11 | -$0.16 | Miss |
| May 13, 2026 | -$0.10 | -$0.09 | Beat |
| Mar 27, 2026 | -$0.13 | -$0.13 | Beat |
| Nov 12, 2025 | -$0.17 | -$0.14 | Beat |
| Aug 11, 2025 | -$0.15 | -$0.24 | Miss |
| May 13, 2025 | -$0.19 | $0.28 | Beat |